Introduction
Human Immunodeficiency Virus type 2 (HIV-2) is endemic in West Africa and sporadic in the rest of the world . Compared to [1] [2] [3] [4] individuals infected by HIV-1, those infected by HIV-2 have a slower clinical progression , a lower mortality rate for patients with high [5] CD4 T lymphocyte count (CD4) and lower rates of transmission . In West African countries, comparisons have shown a , better immune control and lower activation of immune system during HIV-2 infection , , , . These factors might 23-27] [28] [29] [30] [31] [32] [33] [12 23 28 34] be associated as cell activation is linked to viral load . However, cell responsiveness to activation might also vary , .
[34] [5 35] All reported differences in the rate of disease progression between the two infections are from cohort studies performed in sub-Saharan Africa. No direct comparison has been made in Europe or the United States during the course of the infection, although the environment may play a role in the difference of pathogenicity between the two infections. For instance, the level of lymphocyte activation is higher in Africa than in Europe , consequently the role of activation in the difference between the two infections may be weaker or even [36] reinforced because of different background rates. Therefore, we hypothesized that the differences in viro-immunologic markers levels and evolution could be different in Europe compared to sub-Saharan Africa.
Here, we report the changes in plasma HIV RNA, CD4 and CD8 over time in the French national cohort of HIV-2 infected adult patients compared to individually matched HIV-1 infected patients from the French Aquitaine Cohort.
Methods

HIV cohorts
Data is taken from the ANRS CO5 HIV-2 cohort and the ANRS CO3 Aquitaine cohort . The ANRS CO5 HIV-2 cohort is an [37] [38]
ongoing national prospective study initiated in 1994 in 111 clinical centres in France. Inclusion criteria to the cohort are HIV-2 infection only, age 18 years, residence in France planned for at least 1 year and informed consent available. The ANRS CO3 Aquitaine cohort is an ≥ ongoing prospective study initiated in 1987. Inclusion criteria are HIV-1 infection in patients aged over 18 years, and informed consent available. In the two cohorts, clinical, epidemiological and therapeutic data are collected by standardized questionnaires at each visit to the hospital (every 3 to 6 months according to clinical, immuno-virological and therapeutic status).
Markers quantifications
CD4 count was performed by flow cytometry in the two cohorts. Plasma HIV-1 RNA was quantified mainly by branched DNA assays (Chiron Quantiplex RNA HIV-1, Emeryville, CA, USA) with detection limits of 2.7 log copies/ml (500 copies/ml) or 1.7 log copies/ml 10 10 (50 copies/ml). Although there is one commercial kit, designed for HIV-1, which can also quantify only HIV-2 subtype A RNA, there is no commercial assay specifically designed for HIV2 viral load . Plasma HIV-2 RNA quantification was performed using HIV-2 strain
NIHZ as a standard (Advanced Biotechnology Incorporated, Maryland, USA) with lower detection limits of either 2.4 log copies/ml (250 10 copies/ml) or 2.0 log copies/ml (100 copies/ml) .
[39]
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Study populations
We defined three study populations in each cohort: (1) seroincident patients, (2) seroprevalent and (3) naive patients starting a
Combined Anti Retroviral Treatment (CART: combination of 2 nucleoside inhibitors and 1 protease inhibitor or 3 nucleoside inhibitors).
The seroincident group included all seropositive patients whose date of seroconversion was known or well estimated, based on the period between the last negative and the first positive antibody test of less than 3 years. This population was defined retrospectively according to the availability of negative serology in the patients already included in each cohort. Data was collected from date of seroconversion and censored after 3 years of follow-up to avoid any informative dropout . In this group, no patient started an antiretroviral treatment or [42] died before the censoring date. The seroprevalent group included all seropositive untreated patients, and without documented date of HIV infection. Data was collected from inclusion and was censored if patient started an antiretroviral treatment or died. The last group included all HIV antiretroviral-naive patients who started an antiretroviral therapy consisting of at least 3 antiretroviral drugs. Data was collected from the date of first CART regimen initiation and was censored if the antiretroviral treatment was modified or if the patient died. An intent-to-continue analysis was also performed and results were similar (data not shown).
HIV-1 infected patients were inividually matched to HIV-2 infected patients according to factors known to be associated with HIV-1 disease progression , . CART regimen initiation (for group 3). For each HIV-2 infected patient, one (for group 3) to two (for group 1 and 2) HIV-1 infected patients were randomly selected for matching among eligible candidates. We selected only one HIV-1 patient for each HIV-2 patient in group 3 because of the restricted number of available patients. All HIV-1 infected patients who were prescribed a non-nucleoside inhibitor in their CART regimen were excluded, this class of antiretroviral drugs being not active against HIV-2 infection .
[45]
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Comparison between HIV-1 and HIV-2 in France AIDS. Author manuscript Page / 3 11 We carried out two sub-analyses to account for additional factors. For group 2, in addition to sex, age and HIV transmission group, we constituted a new study population by matching for country of birth (West Africa, Europe and others). This sub-analysis was not feasible in group 1 and 3 because of the restricted number of available patients. In group 3, we performed an additional match according to the baseline plasma viral load at treatment initiation (>3.5 vs. 3.5 log copies/ml).
Statistical analysis
Changes in biological markers were studied using piecewise linear mixed models. The baseline (t 0) was the date of seroconversion = for group 1, the date of inclusion for group 2 and the date of first CART regimen initiation for group 3. Trends in the evolution of markers were fitted using one slope (in unit/year) for the first two groups. For the last group of treated patients, two slopes were considered: one for the early change (in unit/month) and a second for the long-term trend (in unit/year). The time taken for the slope to change (t 2 months) = was determined for all patients by a likelihood profile. The correlation between individual baseline value(s) and the subsequent slope(s) was handled through the unstructured covariance matrix of random effects. The left-censoring of plasma viral load due to undetectable values was taken into account using a maximum likelihood method as previously described . Adjustment for the type of assay used to [46] quantify viral load did not modify the estimates of the slopes (data not shown). Data analyses were conducted with SAS 8.1 (SAS Institute, Cary, NC, USA).
Results
Study population
In January 2006, the ANRS CO5 HIV-2 cohort had recruited 572 patients. Of these, 89 were seroincident patients, of whom 49 were antiretroviral-naive at inclusion in the cohort (group 1 
Seroincident patients
Median delay between seroconversion and first available laboratory measure was significantly shorter for HIV-1 infected patients than for HIV-2 ( ): 4.1 years vs. 6.8 years (p<10 ). Without administrative censoring, the median follow-up was 36 months and 81 Table 2 4 − months for HIV-1 and HIV-2 respectively. During the first three years of follow-up, a median of four biological measurements per patient were available among HIV-1 and HIV-2 patients. The proportion of undetectable viral load measures were 14 and 85 in HIV-1 and % % HIV-2 infected patients, respectively. At enrolment in the cohort, median viral load was 4.11 log copies/ml for HIV-1 and 2.09 log 10 10 copies/ml for HIV-2 and median CD4 count was 399 cells/mm and 585 cells/mm for HIV-1 and HIV-2 respectively. 3 3 Mean slopes estimated using linear mixed models were as show in . CD4 count and CD4 percentage significantly decreased in table 3 the HIV-1 group ( 49 cells/mm /year and 1.01 /year) but was quite stable in HIV-2 group ( 9 cells/mm /year and 0.04 /year). On
average, plasma viral load was quite stable over time in the HIV-1 group and in HIV-2 ( 0.02 and 0.06 log copies/ml/year, − + 10 respectively). CD8 count did not change significantly in both groups ( ). Hence, the CD4:CD8 ratio decreased significantly in Table 2 HIV-1 group ( 0.06/year) whereas it did not change in HIV-2 group (0.02/year, p<10 ).
Seroprevalent patients
Median delay between inclusion into the study and the first measurement of CD4 count was 2 months for HIV-1 and 6 months for HIV-2. During the follow-up (median of 4.9 years for HIV-1 and 2.9 for HIV-2), a median of four measurements were available for HIV-1 and seven for HIV-2. At inclusion into the study, the proportion of patients with undetectable plasma viral load was 9 and 39 for not differ between the two groups (p 0.44). The CD4:CD8 ratio decreased over time in the two groups, but it was more pronounced in the = HIV-1 group: 0.06/year vs. 0.02 (p 10 ). We performed a second match including country of birth as a matching variable and results
were similar. In addition, we looked at any modification of the effect of the type of infection (HIV-1 or HIV-2) on the slopes of each marker according to the country of birth and none were significant.
Patients starting CART regimen
At the initiation of CART, the observed median CD4 count was not significantly different in the two groups ( , p 0.06), as well table 2 = as CD4 percentage (p 0.70). Plasma viral load was significantly higher in the HIV-1 group (p<10 ). During the first two months of Table   ) . CD8 count was stable and did not differ significantly between the two groups (p 0.26). The CD4:CD8 ratio increased significantly in 3 = the two groups: 0.11/month for HIV-1 vs. 0.06 for HIV-2.
+ +
After the first two months of CART, in HIV-1 infected patients, CD4 count and CD4 percentage continue to increase: 46 cells/mm
/year and 3.3 /year, respectively. Plasma HIV RNA: 1.13 log copies/ml/year and CD8 count: 100 cells/mm /year decreased slightly.
Therefore, the CD4:CD8 ratio increased significantly: 0.16/year. In HIV-2 infected patients, all these markers were stable ( ).
+ Table 4 Indeed, there was no further increase in CD4 count ( 2.88 cells/mm /year). Among the 24 (60 ) patients who reached a viral load below Changes in markers were not modified according to the treatment type, i.e. with or without protease inhibitor (data not shown). In a secondary analysis, we matched patients according to plasma viral load >3.5 log copies/ml (54 of HIV-1 and 24 of HIV-2 patients) 10 % % and results were similar.
Discussion
We compared the changes in viro-immunologic markers between individuals infected with HIV-2 and individuals infected with HIV-1, all being followed in France. During natural history of infection, the estimated rates of CD4 decrease were much more [23 24 47 48] and HIV-2 groups in the present study were also similar to those reported in a seroincident cohort of female sex workers in Senegal .
[18]
A novel aspect of this study is the estimation of slopes for each marker. Here again, these estimations were similar to those reported in Senegal with a decline of 13 in T-cell count in HIV-1 infected patients (16 in ) and 3.7 in HIV-2 infected patients (4.1 in
). However, Gottlieb et al. reported similar slopes in both infections when controlling for plasma viral load levels. In our study, 48] however, neither baseline plasma viral load (according to the following categories: <2.7, 2.7 3.7, >3.7, p 0.44) nor baseline CD4 count -= (<200, 200 500, >500, p 0.17) influenced the effect of either HIV-1 or -2 on CD4 slopes in seroprevalent patients. In other words, the -= differences in CD4 count decline between the two infections were similar whatever the viral load or CD4 count at the time of enrolment into the cohort.
The difference in pathogenicity between the two types of virus may be independent of environment because, in this study, the differences between the natural history HIV-1 and HIV-2 infection were similar for patients from the same geographic area. However, this study did not explore the respective roles of the host and the virus in determining the differences between the two infections. Whether differences in pathogenicity are mainly due to viral replication, viral infectivity, cell susceptibility to activation, or CTL response remains unknown.
The virological response to CART was weaker in HIV-2 patients whatever the initial HIV RNA level. This result has been previously reported decrease of 0.6 log copies/ml and an increase of 80 cells/mm for CD4 count, two months after the beginning of therapy in HIV-2 . Indeed, it could be expected that a more potent regimen leading to [63] better virological control would improve the global response to treatment. However, the CD4 count did not increase in response to treatment in HIV-2 patients with controlled viral load during the first 6 months. It should also be noted that HIV-2 patients started an antiretroviral treatment at the same CD4 count as than HIV-1 patients, so they started therapy after a longer duration of infection. This late initiation of antiretroviral therapy in HIV-2 infection might contribute to the poorer response to treatment in particular in the CD4 increase.
Hence, the findings of the present study are in favour of an earlier initiation of HAART treatment in HIV-2 infected patients.
Several limits of this study should be recognized. First, the individual matching was limited to a restricted number of potential confounding factors. We were not able to match for country of birth in all analyses because of the restricted number of patients from West Africa in the Aquitaine cohort. However, we could perform such matching for the seroprevalent group and results were similar. Another limitation was the censoring of follow-up due to change in treatment or death. This may lead to biased estimates of the change in viro-immunological markers. However, the consistency in the estimates of the slopes for each marker between the seroprevalent and seroincident groups, although the censoring was only administrative for this latter group (three years of follow-up), argues in favour of the validity of estimates. Finally, the large number of HIV-2 infected patients with undetectable viral load yielded to insufficient information to reliably estimate the slopes. Therefore, blunted variations in HIV RNA viral load (lower than the usual measurement of 0.5 log 10 copies/ml) need to be explored with more sensitive assays.
In conclusion, this study, the first comparing the evolution of markers between HIV-1 and HIV-2 infected patients outside of Africa, found similar differences between the two infections in Europe and in Sub-Saharan Africa. Although the difference in viral load is consistent across all analyses, the biological mechanism is still a matter of debate. The reduced response to CART in HIV-2 infected patients raises the question of optimal antiretroviral drug regimens and the right time to initiate treatment in HIV-2 infection. A better understanding of the differences in pathogenicity between the two infections may lead to improvements in treating both of them.
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